

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☒ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Vieira Roberto Wandenkolk (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY (Street) REDWOOD CA 94065 CITY (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT] Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 09/01/2026 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner ☒ Officer (give title below) Other (specify below) President, Oncology 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/01/2026		A		138 ⁽¹⁾	A	\$113.38 ⁽²⁾	4,206 ⁽³⁾	D	
Common Stock	09/01/2026		A		138 ⁽⁴⁾	A	\$0.00	4,344 ⁽³⁾	D	
Common Stock	09/02/2026		F ⁽⁵⁾		102	D	\$113.38 ⁽⁶⁾	4,242 ⁽⁷⁾	D	
Common Stock	09/02/2026		M		58,333	A	\$21.63	62,575 ⁽⁷⁾	D	
Common Stock	09/02/2026		S ⁽⁸⁾		23,600	D	\$109.3506 ⁽⁹⁾	38,975 ⁽⁷⁾	D	
Common Stock	09/02/2026		S ⁽⁸⁾		23,770	D	\$110.7004 ⁽¹⁰⁾	15,205 ⁽⁷⁾	D	
Common Stock	09/02/2026		S ⁽⁸⁾		1,537	D	\$111.3733 ⁽¹¹⁾	13,668 ⁽⁷⁾	D	
Common Stock	09/02/2026		S ⁽⁸⁾		974	D	\$112.3966 ⁽¹²⁾	12,694 ⁽⁷⁾	D	
Common Stock	09/02/2026		S ⁽⁸⁾		1,606	D	\$113.7187 ⁽¹³⁾	11,088 ⁽⁷⁾	D	
Common Stock	09/02/2026		S ⁽⁸⁾		5,621	D	\$114.5779 ⁽¹⁴⁾	5,467 ⁽⁷⁾	D	
Common Stock	09/02/2026		S ⁽⁸⁾		1,225	D	\$115.4395 ⁽¹⁵⁾	4,242 ⁽⁷⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock option (right to buy)	\$21.63	09/02/2026		M		58,333	(16)	02/01/2034	Common Stock	58,333	\$0.00	141,667	D	

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
3. Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
6. The closing price on September 1, 2026 was used to calculate the withholding obligation.

16. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.

The power of attorney under which this form was signed is on file with the Commission.

** Signature of Reporting Person Date

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.